Hori­zon low­ers ex­pec­ta­tions for Te­pez­za and ad­justs its strat­e­gy for the year ahead

One of Hori­zon Ther­a­peu­tics’ top sell­ers isn’t per­form­ing as well as ex­pect­ed, CEO Tim Wal­bert re­vealed on Wednes­day’s Q2 call, lead­ing the phar­ma com­pa­ny to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER